by Andrea Marra | Jul 26, 2023 | Clinical, CRO, Molecular, Pharmaceutical
At any given time, one in five people in the US has a sexually transmitted infection (STI), translating to more than 60 million infections per year.1 These infections cost billions in healthcare expenses each year. Even more alarming, over 40% of all new STIs in this...
by Andrea Marra | May 3, 2023 | CRO, Pharmaceutical
We take it for granted that in the age of antibiotics there will always be a drug available to treat an infection. But reports of outbreaks of a pan-resistant fungal disease known as Candida auris– that is resistant to every antifungal medication physicians have to...
by Andrea Marra | Mar 24, 2023 | CRO, Pharmaceutical
The bacterial pathogen Mycobacterium tuberculosis (Mtb) has plagued humans for probably 70,000 years and remains a global threat to this day.1, 2 In 1882, Robert Koch recognized Mtb as the causative agent of tuberculosis (TB), but it took decades for the first...
by Andrea Marra | Dec 14, 2022 | Molecular, SARS-CoV-2
Perhaps you have heard that we could be facing a potential “tridemic,” with SARS-CoV-2 (COVID-19), Flu A/B, and a lesser-known third virus–respiratory syncytial virus, or RSV–set to be swirling around us at the same time in the fall/winter of 2022 – 2023. RSV has...
by Andrea Marra | May 14, 2021 | Clinical, CRO, Molecular, Pharmaceutical
What if the latest tech device had all the bells and whistles everyone wanted and was far better than anything currently being sold, but the marketer was told he could not sell it until all the previous versions of his device had broken? And then, he had to sell his...
